A House Appropriations Committee directive pushes the FDA to accelerate the IND sign-off process for new clinical trials, according to the report. The move is framed around maintaining US development speed versus China and other global competitors. The directive highlights how regulatory throughput—not just review timelines for later-stage applications—has become a central operational constraint for biotech. Sponsors and CROs are likely to adjust planning and resourcing as IND timelines become a renewed focus. The directive also increases pressure on compliance and submission quality because faster sign-off can amplify the impact of incomplete packages, requiring tighter internal governance around trial readiness.